항체 약물 접합제 시장 - 규모, 점유율, 성장 분석 : 제품 유형별, 링커 유형별, 타겟 유형별, 페이로드 유형별, 질환 유형별, 지역별 산업 예측(2024-2031년)
Antibody Drug Conjugates Market Size, Share, Growth Analysis, By Product, By Linker Type, By Target Type, By Payload Type, By Disease Type, By Region - Industry Forecast 2024-2031
상품코드:1593452
리서치사:SkyQuest
발행일:2024년 11월
페이지 정보:영문 208 Pages
라이선스 & 가격 (부가세 별도)
한글목차
항체 약물 접합제(ADC) 세계 시장 규모는 2022년에 84억 1,000만 달러로 평가되었고, 2023년 97억 달러에서 2031년에는 300억 9,000만 달러로 성장해 예측 기간(2024-2031) 년)의 CAGR은 15.2%로 성장할 전망입니다.
세계 암 환자의 급증과 혁신적인 의약품에 대한 수요 증가가 향후 수년간 항체 약물 접합제(ADC) 시장의 대폭적인 성장을 가속할 것입니다. 기술의 진보가 결합되어 시장 역학은 더욱 강화될 것입니다. 또한, 신속한 승인 경로의 도입으로 ADC가 시장에 도달할 때까지의 시간이 크게 단축되고 예측 기간을 통해 매출이 증가할 것으로 예상됩니다. 의료로 이러한 동향 증가와 그 채용 확대는 ADC 시장의 개척을 뒷받침할 것으로 보입니다. 그리고 ADC 기업의 세계 성장을 방해할 수 있습니다. 이해관계자가 이러한 복잡한 상황을 극복하면서 ADC 시장은 기술 혁신과 효과적인 암 치료에 대한 긴급한 요구가 원동력이 되는 유망 기회를 제시합니다.
목차
소개
조사의 목적
정의
시장 범위
조사 방법
정보 조달
2차 데이터 소스와 1차 데이터 소스
시장 규모 예측
시장의 상정과 제한
주요 요약
시장 개요 전망
공급 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 역학
성장 촉진요인
기회
억제요인
과제
Porter's Five Forces 분석
주요 시장 인사이트
주요 성공 요인
경쟁도
주요 투자 기회
시장 생태계
밸류체인 분석
기술 분석
특허 분석
가격 분석
고객 및 구매 기준 분석
PESTEL 분석
항체 약물 접합제 시장 : 제품별
시장 개요
Kadcyla
Enhertu
Adcetris
Padcev
Trodelvy
Polivy
기타 제품
항체 약물 접합제 시장 : 링커 유형별
시장 개요
절단 가능한 링커
절단 불가능한 링커
항체 약물 접합제 시장 : 타겟 유형별
시장 개요
HER2
CD22
CD30
기타 타겟 유형
항체 약물 접합제 시장 : 페이로드 유형별
시장 개요
모노메틸 아우리스타틴 E
칼리케아미싱
메이탄시노이드
기타 페이로드 유형
항체 약물 접합제 시장 : 질병 유형별
시장 개요
유방암
혈액암
기타 질환 유형
항체 약물 접합제 시장 : 지역별
시장 개요
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카(MEA)
GCC 국가
남아프리카
기타 중동 및 아프리카
경쟁 구도
상위 5개사 비교
주요 기업의 시장 포지셔닝(2023년)
주요 시장 기업이 채용한 전략
시장에서의 최근 활동
주요 기업의 시장 점유율(2023년)
주요 기업 프로파일
Roche Holding AG(Switzerland)
Daiichi Sankyo Company, Limited(Japan)
Gilead Sciences, Inc.(US)
Takeda Pharmaceutical Company Limited(Japan)
Pfizer Inc.(US)
Astellas Pharma Inc.(Japan)
AstraZeneca(UK)
ADC Therapeutics SA(Switzerland)
ImmunoGen, Inc.(US)
Zydus Group(India)
AbbVie Inc.(US)
Ambrx(US)
LegoChem Biosciences, Inc.(South Korea)
Byondis(Netherlands)
ProfoundBio(US)
RemeGen(China)
Sutro Biopharma, Inc.(US)
Lepu Biopharma Co., Ltd.(China)
Zymeworks Inc.(Canada)
Mersana Therapeutics(US)
Duality Biologics(China)
Lanova Medicines(China)
Exelixis, Inc.(US)
BioNeCure Therapeutics Inc.(US)
Tripartite Therapeutics, Inc.(US)
JHS
영문 목차
영문목차
Global Antibody Drug Conjugates (ADC) Market size was valued at USD 8.41 billion in 2022 and is poised to grow from USD 9.70 billion in 2023 to USD 30.09 billion by 2031, growing at a CAGR of 15.2% in the forecast period (2024-2031).
The global surge in cancer cases and the rising demand for innovative pharmaceuticals are set to catalyze substantial growth in the antibody drug conjugates (ADCs) market in the coming years. Increased investments in biopharmaceutical research, coupled with advancements in ADC development technologies, will further enhance market dynamics. Moreover, the introduction of expedited approval pathways is expected to significantly reduce the time required for ADCs to reach the market, facilitating increased sales throughout the projected period. Additionally, the growing trend toward personalized medicine and its expanding adoption is likely to support the development of the ADC market. However, the sector faces challenges, including high developmental costs, safety concerns regarding toxicity, as well as stiff competition from biosimilars, which may hinder the growth of ADC companies globally. As stakeholders navigate these complexities, the ADC market presents a promising opportunity driven by innovation and the urgent need for effective cancer therapies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Drug Conjugates (Adc) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Antibody Drug Conjugates (Adc) Market Segmental Analysis
Global Antibody Drug Conjugates (ADC) Market is segmented on the product, linker type, target type, payload type, disease type, and region. By product, market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Other Products. By linker type, market is segmented into Cleavable Linkers and Non-Cleavable Linkers. By target type, market is segmented into HER2, CD22, CD30, and Other Target Types. By payload type, market is segmented into Monomethyl Auristatin E (MMAE), Calicheamicin, Maytansinoids, and Other Payload Types. By disease type, market is segmented into Breast Cancer, Blood Cancer, and Other Disease Types. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Driver of the Global Antibody Drug Conjugates (Adc) Market
The rising global incidence of cancer is a significant market driver for the Global Antibody Drug Conjugates (ADC) market. As cancer continues to pose a formidable public health challenge, there is an escalating demand for innovative and targeted therapeutic options. This urgency has catalyzed extensive oncology research, leading to the development of advanced ADCs that combine the specificity of monoclonal antibodies with potent cytotoxic drugs. Consequently, the growing emphasis on personalized medicine and precise cancer management is expected to significantly enhance the adoption and sales of ADCs, creating robust growth prospects in this specialized therapeutic market segment.
Restraints in the Global Antibody Drug Conjugates (Adc) Market
The Global Antibody Drug Conjugates (ADC) market faces significant restraints due to the high operational costs associated with their manufacturing. The production of ADCs demands specialized equipment, advanced facilities, and a highly skilled workforce, all of which entail substantial capital investment. These elevated costs not only make the production process more expensive but also contribute to higher prices for end products, limiting accessibility and adoption in healthcare settings. Consequently, this financial burden restrains market growth by restricting investment from smaller companies and deterring potential market entrants, ultimately slowing down the overall development and expansion of the ADC market.
Market Trends of the Global Antibody Drug Conjugates (Adc) Market
The global Antibody Drug Conjugates (ADCs) market is witnessing a significant trend towards expanding applications beyond oncology, targeting various chronic diseases to broaden therapeutic horizons. As companies invest in developing ADCs for indications such as autoimmune disorders and infectious diseases, a lucrative landscape is emerging with ample opportunities for innovation. Additionally, the rising demand for combination therapies further propels ADCs into the spotlight, as their ability to enhance efficacy and improve patient outcomes positions them as valuable assets in holistic treatment approaches. This dual advancement is set to drive market growth, creating a dynamic and competitive environment for ADC manufacturers.
